Dr. Reddy’s Laboratories Limited (Dr. Reddy's) commenced its generics business in India in 1986 and is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high quality, affordable and innovative medicines across therapy areas. The company’s shares trade on the Bombay Stock Exchange and the National Stock Exchange in India and on the New York Stock Exchange in the United States. The company is a global pharmaceutical company headquartered in Hyderabad, India. Guided by its purpose of Good Health Can't Wait, it is committed to accelerating access to affordable and innovative medicines. Its portfolio spans APIs, generic formulations including biosimilars, OTC products, innovative products, and custom pharmaceutical services, with a focus on key therapeutic areas including gastrointestinal, cardiovascular, and oncology. Its major markets include the USA, India, Russia & CIS, China, Brazil, and Europe.

Business area of the company

The company is a multinational pharmaceutical company that manufactures and markets a wide range of pharmaceutical products and services. Through its businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations. The company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.

Business verticals 

Generics: The company is committed to making medicines more accessible and affordable. Its generics business focuses on delivering products that meet unmet patient needs, supported by a strong pipeline and a sustainable model built on market leadership, innovation, and efficiency.

API & Services: Its API business supports global healthcare by supplying high-quality ingredients to leading pharmaceutical companies. Since 1984, it has combined scientific expertise with reliable manufacturing to serve both its own formulations and those of its partners. Recognised within the industry, it continues to focus on quality, compliance, and long-term collaboration.

Innovative Medicines: The company is committed to expanding access to cutting-edge therapies by working closely with global innovators. Through strategic collaborations, it aims to bring novel treatments to India and other emerging markets, helping patients and healthcare providers address unmet needs and manage diseases better.

Consumer Health: The company made its first foray into the nutrition space in India with a diabetic nutrition supplement, CELEVIDA, in Nov 2019, following which it entered the hospital nutrition segment in July 2020 with CELEVIDA Maxx, in its endeavor to continue making a positive impact on patient lives.

Patient Programs: Empowering patients through support, care, and education. Alivius: An integrated digital cancer care platform designed to support patients and healthcare professionals throughout the treatment journey. It combines remote monitoring, treatment management, and mental health support into a seamless experience, helping patients track their health, manage side effects, and access personalized resources. With clinically validated tools and real-time alerts, Alivius enhances care coordination, empowers informed decision-making, and improves overall quality of life for cancer patients across multiple geographies. Joint Health Revolution: The program supports people living with osteoarthritis by helping them understand how to care for their joints. These doctor-led sessions help patients learn about the right exercises, healthy habits, and ways to manage pain, and stay active.

Healthcare professionals programs: The company conducts across the world for healthcare professionals. MedEngage: An education ecosystem for healthcare professionals, built to support learning, collaboration, and clinical excellence. It includes region-specific platforms like DocVidya in India, MedEnrich in Spain, Medepro in South Africa, and Medznat in Russia. Each one is tailored to local needs while offering trusted, evidence-based content. Through certified courses, expert webinars, and interactive communities, MedEngage helps doctors stay updated, upskill, and deliver better care. Medenrich: A video-based medical learning platform that gives short, expert-led content for busy healthcare professionals. It features trusted insights from global and local experts to support ongoing learning and better patient care.

Awards & Recognitions

• 2017: India’s Best Companies to Work For in the Biotechnology and Pharmaceuticals sector by Great Place To Work Institute.
• ‘Best Places to Work’ in 2017 in New Jersey by NJBIZ.
  
• 2018: Global Generics & Biosimilar Award 2018 for CSR initiative of the year
  
• 2018: India Pharma Corporate Social Responsibility (CSR) programme of the year Award 2018 by Department of Pharmaceuticals, Government of India.
  
• 2018 Dr. Reddy’s ranked among the top 10 in the Forbes China 2018 list of leading Indian Companies in China.
  
• 2019: Dr. Reddy’s inclusion in the 2019 Bloomberg Gender-Equality Index.
  
• 2019: Global Generics & Biosimilars Award 2019: API supplier of the Year at the 6th Annual Global Generics & Biosimilars Awards.
  
• 2019: Winner of Golden Peacock International Award for Sustainability for the year 2019.
• 2021-22: Bloomberg Gender-Equality Index 2022 - only Indian pharma company in the index; featured for 5th year in a row.
• 2021-22: CII Industrial Innovation Awards 2021 – Most Innovative Company.
• 2021-22: Global Generics & Biosimilars Awards 2021 - ‘API Supplier of the Year’ and ‘CSR Initiative of the Year’.
• 2021-22: CDP Supplier Engagement Leaderboard 2022.
• Indo-American Chamber of Commerce 2021 – Indian company in the U.S. for excellence in manufacturing.
• 2022-23: World Economic Forum - Recognised its largest manufacturing facility in Bachupally, Hyderabad as part of its Global Lighthouse Network for deployment of Industry 4.0 technologies.
• 2022-23: Awarded by the President of India - For its work in the empowerment and employment opportunities for persons with disabilities through Dr. Reddy’s Foundation.
• 2022-23: Global Generics & Biosimilars Awards 2022 - Recognised as ‘Company of the Year - Americas’.
• 2022-23: Analytics India Magazine 2022 - Recognised as a ‘Best Firm For Data Scientists.
• 2022-23: India Risk Management Award 2023 - Recognised as Masters of Risk - Healthcare and Pharma.
• 2023-24: Received Gold Medal status from EcoVadis in 2023.
• 2023-24: First Indian pharma company to be included in the Dow Jones Sustainability World Index 2023.
• 2023-24: warded Excellence in Rural Health Initiative at the - 2023 Economic Times India Pharmaworld Awards.
• 2023-24: Included in S&P Global’s Sustainability Yearbook 2024 in the Top 10% category.
• 2023-24: Great Place to Work Certification 2023 – in Colombia, Brazil, China, Malaysia, Thailand, India, Myanmar.
• 2023-24: Best Patient Support Programme at the - 2023 Silver Feather Awards.
• 2024-25: 2nd year in a row feature in The Financial Times (London) ‘Asia-Pacific Climate Leader 2024' list.
• 2024-25: Winner, North America, Candidate Experience Awards 2024.
• 2024-25: Certified Great Place to Work 2025, and recognised as one of India's Best Employers Among Nation-Builders for 2024.
• 2024-25: Russian Pharma Awards 2024 for Medznat Portal for HCPs.
• 2024-25: Winner, AI Pioneer category, LinkedIn Talent Awards.
• 2024-25: Gold award, Best Market Intelligence / Productivity and Effectiveness Project, Lupa de Ouro Awards Brazil.

• 1984: The birth of a dream.
  
• 1991: From molecules to affordable medicines.
  
• 1995: Expanding to reach patients in other countries.
  
• 2001: Spreading wings globally.
  
• 2007: Accelerating access to expensive therapies.
  
• 2010: From medicines to health.
  
• 2012: Strengthening capabilities.
  
• 2014: Re-dedicating to patient-centricity.
  
• 2015: Dr. Reddy’s Laboratories signs commercialization deal with Hatchtech.
  
• 2016: Dr. Reddy’s completes acquisition of product portfolio from TEVA.
  
• 2017: Dr. Reddy's expands commercial operations in Europe.
  
• 2018: Dr. Reddy's Laboratories announces the launch of Tetrabenazine Tablets in the U.S. Market.
  
• 2019: Dr. Reddy’s Laboratories enters Nutrition Segment with Celevida in India.
  
• 2020: Dr. Reddy’s Laboratories joins Science Based Targets initiative (SBTi) and sets 2030 GHG emission targets.
  
• 2021: Its focus on agility, access and affordability helped it reach over 5 million patients during the pandemic, especially in low and middle income countries.
• 2021: the company played its part along with the rest of the pharma industry in the fight against COVID-19.
• 2021: The company combined in-house efforts with open-innovation partnerships to provide a portfolio that included a vaccine and therapeutics for COVID-19.
• 2022: Launched Lenalidomide capsule in the U.S., with two of the six strengths eligible for first-to-market, 180-day exclusivity.
• 2022: Its Hyderabad facility was recognised by the World Economic Forum as part of its Global Lighthouse Network for Industry 4.0 leadership.
• 2023: The company became the first Indian pharma company to debut on the Dow Jones Sustainability World Index.
• 2024: the company partnered with Nestlé India to launch nutritional health solutions in India and other regions.
• 2024: The company Signed a definitive agreement with Haleon Plc to acquire Nicotinell and its Nicotine Replacement Therapy portfolio.
• 2024: the company acquired Menolabs' women's health and dietary supplements portfolio from Amyris Inc. including seven products for perimenopause and menopause support.
• 2025: Dr. Reddy’s arm inks commercialization and license agreements for biosimilars.